While a federal judge has paused the funding cuts, the uncertainty has researchers concerned about the future of scientific ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

NIH grant recipients receive additional funding to cover "indirect costs," such as building maintenance and administrative ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

"Knock Out" features a boy in boxing trunks symbolizing the battle against cancer as LL Cool J's "Mama Said Knock You Out" ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best cancer ...

(Reuters) - Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established to boost the pipeline of Black, Latino and Native American ...

If successful, the trial will position Ab&B to enter a market that is already served by Merck’s 23-valent vaccine Pneumovax and Pfizer’s ... The biotech is seeking funding for the programs ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been underperforming for ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...